GlassScriptPhysician profile
Christopher T Wommack
NPI 1962403808
$5,660.20
in general payments reported to CMS, 2019-2025
33 companies · $447 in 2025
The $447 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $112 · 2020: $715 · 2021: $1,421 · 2022: $899 · 2023: $1,179 · 2024: $887 · 2025: $447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,413 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,412.73 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,401.64 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $610.52 | 2020-2025 | Vraylar, Qulipta, Ubrelvy |
| Lilly USA, LLC | $570.03 | 2020-2025 | Mounjaro, Zepbound, Trulicity |
| Astrazeneca Pharmaceuticals LP | $352.19 | 2020-2024 | Airsupra, Farxiga, Breztri |
| Astellas Pharma US INC | $348.67 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $284.89 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $265.73 | 2020-2025 | Jardiance |
| Glaxosmithkline, LLC. | $232.40 | 2020-2024 | Shingrix, Arexvy |
| Amgen INC. | $224.11 | 2020-2025 | Otezla, Repatha, Evenity |
| Pfizer INC. | $159.24 | 2022-2025 | |
| Medtronic, INC. | $130.69 | 2021-2024 | Venaseal |
| Esperion Therapeutics, INC. | $113.37 | 2020-2023 | Nexletol |
| Abbott Laboratories | $109.77 | 2021-2023 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $103.59 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $89.86 | 2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $83.96 | 2022 | |
| Merck Sharp & Dohme LLC | $79.97 | 2020-2021 | |
| Allergan, INC. | $78.53 | 2020 | |
| Horizon Therapeutics Plc | $67.76 | 2020-2022 | |
| Eisai INC. | $61.16 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $42.45 | 2023 | |
| Exact Sciences Corporation | $31.81 | 2023-2024 | Cologuard Collection Kit |
| Currax Pharmaceuticals LLC | $29.13 | 2020-2024 | Contrave |
| Supernus Pharmaceuticals, INC. | $28.58 | 2021-2023 | Qelbree |
| Janssen Pharmaceuticals, INC | $26.32 | 2022 | |
| Jazz Pharmaceuticals INC. | $24.72 | 2021 | |
| Bausch Health US, LLC | $20.65 | 2021 | |
| Tolmar, INC. | $16.70 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $16.15 | 2021 | |
| Hikma Pharmaceuticals USA | $15.75 | 2024 | Ryaltris |
| Sanofi-Aventis U.S. LLC | $14.76 | 2021 | |
| Nestle Healthcare Nutrition INC. | $13.41 | 2021 | |
| Medtronic USA, INC. | $11.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Wommack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.